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First Trimester Noninvasive Prenatal Diagnosis:
A Computational Intelligence Approach
Andreas C. Neocleous, Kypros H. Nicolaides, and Christos N. Schizas, Senior Member, IEEE
Abstract—The objective of this study is to examine the potential
value of using machine learning techniques such as artificial neural
network (ANN) schemes for the noninvasive estimation, at 11–13
weeks of gestation, the risk for euploidy, trisomy 21 (T21), and other
chromosomal aneuploidies (O.C.A.), from suitable sonographic,
biochemical markers, and other relevant data. A database1 con-
sisted of 51,208 singleton pregnancy cases, while undergoing first
trimester screening for aneuploidies has been used for the building,
training, and verification of the proposed method. From all the data
collected for each case from the mother and the fetus, the following
9 are considered by the collaborating obstetricians as the most rele-
vant to the problem in question: maternal age, previous pregnancy
with T21, fetal crown-rump length, serum free β-hCG in multiples
of the median (MoM), pregnancy-associated plasma protein-A in
MoM, nuchal translucency thickness, nasal bone, tricuspid flow,
and ductus venosus flow. The dataset was randomly divided into
a training set that was used to guide the development of various
ANN schemes, support vector machines, and k-nearest neighbor
models. An evaluation set used to determine the performance of
the developed systems. The evaluation set, totally unknown to the
proposed system, contained 16,898 cases of euploidy fetuses, 129
cases of T21, and 76 cases of O.C.A. The best results were obtained
by the ANN system, which identified correctly all T21 cases, i.e.,
0% false negative rate (FNR) and 96.1% of euploidies, i.e., 3.9%
false positive rate (FPR), meaning that no child would have been
born with T21 if only that 3.9% of all pregnancies had been sent
for invasive testing. The aim of this work is to produce a practical
tool for the obstetrician which will ideally provide 0% FNR and
to recommend the minimum possible number of cases for further
testing such as invasive. In conclusion, it was demonstrated that
ANN schemes can provide an effective early screening for fetal
aneuploidies at a low FPR with results that compare favorably to
those of existing systems.
Index Terms—Bioinformatics, chromosomal abnormalities,
computational, intelligence, non-invasive prenatal diagnosis.
I. INTRODUCTION
THE identification of chromosomal abnormalities in theearly stages of pregnancy can be achieved, with high con-
fidence, by performing an amniocentesis test or a chorionic
1The dataset can become available for academic purposes by communicating
directly with the authors.Digital Object Identifier 10.1109/JBHI.2015.2462744
1Manuscript received December 3, 2014; revised June 11, 2015; accepted July
21, 2015. Date of publication July 29, 2015; date of current version September
1, 2016.
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villus sampling test (CVS) [1]. These methods, however, are
invasive and carry high risk for miscarriage or cause medical
side effects to the pregnant woman.
A. Invasive Methods
In the work of Tabor and Alfirevic [2], it is reported that
amniocentesis and CVS have a miscarriage rate of 0.5–1.0%.
Furthermore, the amniocentesis test should not be performed
prior to the 15 weeks of pregnancy since the miscarriage rate
increases significantly, while there is also increased risk of de-
veloping talipes equinovarus [3].
Therefore, the amniocentesis or the CVS test should not be
performed unless there are serious indications of high risk for
chromosomal aneuploidy in the fetus. It is also emphasized that
both of these methods carry additional costs to the family, which
is not a trivial issue.
B. Noninvasive Methods
There has been an increased interest and need of exploring
noninvasive methods for the prediction of chromosomal ane-
uploidies in the first trimester, or earlier, of pregnancy. In the
literature, several methods that were aiming at a noninvasive pre-
diction of chromosomal abnormalities had been reported. These
methods can be classified into three main categories, based on
their methodology.
1) First-Trimester Prenatal Statistical Screening: Statistical
methods for appraising the probability of aneuploidy are prop-
erly applied on several markers that are obtained by an antenatal
test. Typically, the markers used are the fetus crown ramp length
(CRL), the fetal nuchal translucency (NT), the maternal age
(MA), the pregnancy-associated plasma protein-A (PAPP-A),
the serum free β-hCG, the ductus venosus flow (DV), tricus-
pid valve flow, and others [4]–[6]. The risk for aneuploidies
increases with MA, and it is higher in women with previous
affected pregnancies. It also increases with fetal NT thickness
and is higher in those with absence of the fetal nasal bone and
with abnormal flow through the ductus venosus and across the
tricuspid valve. The maternal serum concentration of the placen-
tal products free β-human chorionic gonadotropin and PAPP-A
also influence the risk for aneuploidy [4]. Serum PAPP-A is de-
creased in trisomies 21, 18, 13 and the Turner syndrome, while
serum free β-hCG is increased in T21, decreased in trisomies
18 and 13 and not altered in the Turner syndrome.
Most of these methods use posterior probabilities based on
the median and the standard deviation of the markers, or by
using a suitable multivariate statistical approach. Typically, the
models output a probability on the risk of fetus aneuploidy.
In the work of Nicolaides et al. [7], a multivariate likelihood
2168-2194 © 2015 IEEE. Translations and content mining are permitted for academic research only. Personal use is also permitted, but republication/redistribution
requires IEEE permission. See http://www.ieee.org/publications standards/publications/rights/index.html for more information.
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approach is described for the identification of the T21 in the
first trimester of pregnancy. A multiplication of the MA-related
risk and each likelihood ratio (LR) derived from the fetal NT
and maternal weight-adjusted serum free β-hCG and PAPP-A
outputs the patient-specific risks for aneuploidy. More on this
method can be found in [8].
Traditionally, screening for aneuploidies is done by estimat-
ing the patient-specific risk for each aneuploidy. This is done
by multiplying the a priori risk, by a factor of approximately
1.75 in cases with a previous history of aneuploidy. The LR for
each ultrasonographic and biochemical marker is used to calcu-
late the detection and false positive rates (FPRs) by taking the
proportions with risks above a given risk threshold [4]. The LRs
for the categorical variables, such as the absence or presence of
nasal bone and the abnormality of flow in the tricuspid or ductus
venosus valves, are ratios of prevalence of each marker in each
type of fetal aneuploidy to the prevalence in euploidy fetuses. In
the case of continuous variables, such as fetal NT thickness and
maternal serum free β-hCG and PAPP-A, the LRs are derived
from the overlap of the Gaussian distribution of each marker
in each type of fetal aneuploidy with the respective Gaussian
distribution in euploidy fetuses.
2) Maternal Cell-Free DNA Screening: Schmorl’s experi-
ment with women who died of eclampsia was the first study to
suggest that fetal cells circulate in the mother’s blood [9]. It is
estimated that 1 in 1000 to 1 in 10 000 000 nucleated cells in ma-
ternal blood are fetal [10]. The isolation of fetal DNA from the
maternal DNA could give insights for studying genetic diseases.
For the problem under study, the isolation of the fetus DNA is
still extremely hard to achieve; it is labor intensive and requires
highly skilled operators. While the majority of the studies fo-
cused on the identification of the T21 [11], [12], recently, the tri-
somies 18 and 13 are also identified. In [13], Papageorgiou et al.
claim a very good prediction (100%) of 26 euploidy and 14 cases
of T21 in the validation set, by determining the DNA methyla-
tion ratio of 12 selected differentially methylated regions.
Other studies used similar approaches, mainly for T21, tri-
somy 18, and trisomy 13 [14]–[16]. Palomaki et al. [16] report
a detection rate of 100% for trisomy 18 and 91.7% for trisomy
13 with an FPR of 0.28% and 0.97%, respectively. However,
the test was done in the late first and early second trimester
of the pregnancy, which can be considered relatively late for
abortion. Most importantly, the circulating cell-free DNA frag-
ments are being presented as differentially methylated markers
and not identified under microscope. Then, the procedure for
the prediction of the risk for aneuploidies is done with simple
statistical analysis of the methylated markers.
The above-described noninvasive methodologies have their
relative advantages but at the same time have their disadvan-
tages. The first methodology suffers in the sense that one cannot
combine and examine simultaneously all the relevant parame-
ters of the case or visualize them in a multidimensional space.
Visualization of more than three parameters at a time is ex-
tremely difficult and not practical in a medical environment.
Also, parameters that are correlated can lead to unreliable con-
clusions. In the second methodology, the parameters used (called
markers) have no relation to the phenotype of the fetus, such as,
for instance, the CRL or the fetal heart rate which for the certain
problem is important. In the majority of the published studies,
the population of their databases is very small for drawing re-
liable conclusions for such a complex problem. For instance,
in [10], they are dealing with 40 cases (euploidy and T21).
Even though this work was published in Nature Medicine, one
can identify two important limitations of the proposed method,
which imply lack of scientific confirmation. For such a com-
plex problem, it is not convincing whether a perfect prediction
of a population of 40 cases is satisfactory for drawing robust
conclusions. In contrast to this database, we studied more than
51 000 cases of pregnant women and validated 16 898 cases of
euploidy fetuses, 129 cases of T21, and 76 cases of O.C.A. Also,
there is no information in [13] whether the results were cross
validated. It is important to present cross-validated results such
as tenfold or leave-one-out cross validation. In this scenario, one
can have a better insight about the generalization ability of the
method. Therefore, it is not explicit if their method will yield
similar results by randomly selecting different training and test
sets. Another serious limitation of the study [10] is the fact that
only euploidy and T21 can be handled; what will the system
predict if the unknown case in question is trisomy 13 or O.C.A.
Furthermore, even though the whole analysis is based on the
existence of free DNA cells of the fetus in the mother’s blood,
no such cell is isolated for singling out the pathological gene.
The determination of a pathological existence in the genes is
done statistically and probabilistically.
3) Computational Intelligence: In this study, we report a
computational intelligent approach for the noninvasive estima-
tion of the risk of aneuploidies. This approach involves the
development of a system predictor, which takes as input a num-
ber of parameter values. These values have different origins
and source, and they are collected at certain prespecified times
during pregnancy. For example, during the first-trimester screen-
ing for fetal T21 and for O.C.A., certain parameter values are
recorded, which are a combination of maternal and fetoplacental
nature [4].
The computational artificial neural networks (ANNs), which
are a specific paradigm of computational intelligence, had been
used as effective classifiers and predictors for the last 25 years.
Indeed, they had been extensively applied in medical and bio-
logical research and applications [17]–[20].
ANNs are essentially mathematical algorithms implemented
in software that learn from data and capture the knowledge
and the internal dynamics that are contained in the data. Suit-
ably trained models approach the functionality of small biolog-
ical neural systems in a very fundamental manner that mimics
human-like behavior. Thus, once they are properly trained, they
exhibit computational intelligence in a simplistic mimicry of
the biological intelligence. They constitute a very simple dig-
itized model of the biological brain and, in some cases, can
detect complex nonlinear relationships between dependent and
independent variables in a dataset which may be undetectable
by a human brain. Indeed, they can execute certain tasks, espe-
cially in classification and recognition that would be extremely
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difficult to be done by the traditional and conventional comput-
ing techniques. They can learn from data, even in self-organized
manners.
In the medical field, ANNs proved to be a powerful method
for medical diagnosis. As an example, Al-Shayea [21] reports a
medical diagnosis system for acute nephritis disease and heart
disease using feedforward ANN. A correct classification of 99%
has been reported. Hayashia and Setiono [22] used a two-level
approach combining two ANN systems for the diagnosis of hep-
atobiliary disorders. In this study, the database consisted by 536
samples with 9 input features describing four hepatobiliary dis-
orders: Alcoholic Liver Disease, Primary Hepatoma (PH), Liver
Cirrhosis, and Cholelithiasis. Their best ANN models classified
95% of the four diseases. A chest disease diagnosis system is
reported in [23]. The database in this work consisted of chest
disease measurements of 357 samples and 6 classes, namely
Tuberculosis, COPD, Pneumonia, Asthma, Lung Cancer, and
Normal. All samples had 38 features. The authors report 90.2%
average classification accuracy for all the 6 classes. Other stud-
ies that used ANN are referenced in [24]–[26].
The objective of our study is to examine the potential value
of ANNs and other computational intelligence techniques in the
prediction of the risk for T21 and O.C.A. from ultrasonographic
and biochemical markers at 11–13 weeks of gestation.
In Section II, computational intelligence approach and the
proposed method are presented and discussed. Furthermore, sta-
tistical analysis has been applied to the nonbinary features. This
analysis is presented including the visualization of the feature
distributions and the testing of the separability of the features
in pairs. In Section III, we present our experiments and results,
and in Section IV, we discuss further the results of the present
work and how it is compared with other methods. Finally, in
Section V, we report our conclusions.
II. METHODS
In this section, we present the computational intelligence ap-
proach that has been adopted, the procedure for data collection,
the data grouping into cross-validation sets, and two schemes
for aneuploidy risk prediction. We have implemented models
with ANNs, support vector machines (SVM) (kernel 1 and 2),
and k-nearest neighbors (k-NN).
A. ANN Diagnostic System
Many different ANN structures had been proposed and used
by researchers in different fields. The most widely used ANN
structure is the fully connected multilayer feedforward structure.

















where y[L ]iL is the output value of each neuron i of layer L that has
a total of nL neurons. Typically, the function has a squashing
form such as the logistic or the hyperbolic tangent. WL−1,L is
the set of weights associating neurons in layer L− 1 to neurons
in layer L.
In this study, we used fully connected feedforward ANNs
as described in Eq. 1. The first layer is typically called input
layer and it has as many neurons as the input parameters. The
weights in the ANN represent the intensity of the processes in
the synapses of the biological neural network. In a practical
implementation of ANNs, the initial values of the weights are
typically set to random values.
Once the ANN topology is decided, an effective training and
tuning procedure needs to be implemented, so that the network
will achieve the capability for generalization as a risk estimator.
Many training procedures had been proposed and are avail-
able for implementation. The most widely used for feedforward
networks is the backpropagation algorithm [27]. In this study,
we implemented fully connected feedforward neural networks
with backpropagation learning. The justification for selecting
this simple network is discussed further down in the paper. The
activation function for the input layer and the hidden layer was
set to logistic. We have trained and validated a large number of
networks by changing different parameters in the training pro-
cedure. The best results were obtained with the networks built
with 20 to 40 neurons in the hidden layer as will be explained
in the results.
B. Database and Parameters Used
The dataset used was collected from women having singleton
pregnancies while attending the Fetal Medicine Centre at Kings’
College Hospital and University College London Hospital in
London, for aneuploidy screening at 11+0 to 13+6 weeks of
gestation. The MA and the previous history of the pregnancy,
in particular on whether there was a previous case of T21,
were recorded. Also, a transabdominal ultrasound examination
was performed for measurement of the fetal CRL and the NT
thickness, as well as an assessment of the fetal nasal bone and
the flow in the DV and across the tricuspid valve. These were
done by sonographers who had received the appropriate Fetal
Medicine Foundation Certificates of Competency. The preg-
nancy was dated according to the measurement of the fetal CRL
[28]. Additionally, maternal blood was collected and used to
measure serum PAPP-A and serum free β-hCG concentrations
through automated machines that provide reproducible results
within 30 min (Delfia Express System, Perkin Elmer). The
measured PAPP-A and serum free β-hCG were converted into
multiples of the median (MoM). The measured fetal NT was
expressed as a difference from the expected normal mean for the
specific CRL [29]. These maternal demographic characteristics,
ultrasonographic measurements, and the biochemical results
were recorded in a structured database.
The following 9 parameters were used as suitable markers
that could help in establishing the risk for aneuploidies: MA
in years, history of previous pregnancy with T21, fetal CRL in
mm, serum free β-hCG in MoM, PAPP-A in MoM, delta NT in
mm, nasal bone (present or absent), tricuspid flow (regurgitation
or normal), and DV (reversed a-wave or normal).
C. Statistical Analysis of the Data
In this section, we present the results of a statistical analy-
sis that has been applied to the data. The aim of this analysis
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TABLE I
RESULTS FROM THE KOLMOGOROV–SMIRNOV TEST (NORMALITY TEST). “MA”
STANDS FOR MATERNAL AGE, “N” STANDS FOR NORMAL DISTRIBUTION,
WHILE “NN” STANDS FOR NON-NORMAL DISTRIBUTIONS.
MA CRL PAPP-A β -hCG delta NT
Euploidy NN NN NN NN NN
T13 N N NN N N
T18 N N NN NN N
T21 NN N NN NN NN
Triploidy N N NN NN NN
Turner N N N NN N
is to discover the significance of separability between pairs of
distributions for each feature, by means of their medians, that
is, to test for the statistical null hypothesis whether data that
belong to same category share equal medians. Moreover, we
have tested the normality of the distribution of each feature.
This was done to create a better understanding of our data, as
well as to avoid using methods that require normal distribu-
tions in the input feature space, such as the Gaussian Mixture
Models and the student’ t-test. The histogram of each nonbinary
feature has been computed for all the classes of our database,
namely euploidy, T13, T21, T18, Triploidy, and Turner. The
normality of the data was tested with the Kolmogorov–Smirnov
test [30].
In Table I, the results of the normality test are shown. In the
first row, the names of the five nonbinary markers are shown,
while in the first column, the names of the classes (euploidy or
aneuploidies). It should have been expected that the data used
in this study will not follow a normal distribution since the
population under study is not normally distributed by nature,
since pregnancy occurs in a certain age range which is naturally
skew to the right; in addition to this, the large database used
in this study contains proportionally much more trisomy cases
than reported statistically. For example, T21 occurs 1 in about
800 pregnancies, and thus, in our database, we should have had
65 cases instead of 408. Similarly, trisomy 18 occurs 1 in 5,000
pregnancies, and thus, we should have had ten instead of 145
cases, trisomy 13 1 in about 16,000 pregnancies, etc.
The results of the normality test confirm this reality. Another
factor that may contributed to this is the fact that our database
in highly unbalanced, i.e., euploities are by far more than aneu-
ploidies. In large sample sizes, the probability that a normality
test will reject the null hypothesis that the sample comes from
a normal distribution increases due to samples that depart from
normality, which are statistically significant. Furthermore, the
population in the classes of T13, Triploidy, and Turner is rel-
atively small (< 50), and therefore, the rejection of the null
hypothesis may be because of insufficient number of samples.
A widely used method to measure the seperability between
two classes for a given feature is the student’s t-test. The student’
t-test assumes that the testing data follow a normal distribution
and the population of the two classes is equal. The t-test rejects
the null hypothesis at a confidence level of 95% (p < 0.05),
where p is the estimated probability of rejecting the null
hypothesis.
TABLE II
THE SIGNIFICANCE OF THE DIFFERENCE BETWEEN THE MEDIANS
OF EVERY CLASS COMPUTED BY THE PAIRED-DIFFERENCE
USING THE WILCOXON RANK SUM METHOD










0.08 True 0.14 True <<0.05 False 0.18 True <<0.05
False
T13 - T18 0.14 True 0.28 True 0.02 False <<0.05
False
0.0763 True

































0.32 True 0.04 False <<0.05 False 0.025 False <<0.05
False
Taking into consideration that a subset of the features does
not follow a normal distribution and the population between the
classes is not equal, the t-test could not be applied.
The significance of the difference between the medians of ev-
ery class for the nonbinary features was computed by the paired-
difference Wilcoxon Rank Sum method [31]. The Wilcoxon
Rank Sum method is a nonparametric method in contrast with
the widely used t-test method. It has been proposed by Frank
Wilcoxon in 1945 and popularized by Sidney Siegel in 1956
in applications to behavioral sciences. The p-values of the
Wilcoxon Rank Sum method are summarized in Table II. The
pairs for testing the null hypothesis are shown in the first col-
umn in Table II. The word True signifies rejection of the null
hypothesis and False acceptance. The null hypothesis that the
medians of the data being compared have no statistical signif-
icance is rejected with a p-value that is less than 0.05. The
method rejected the null hypothesis for all the features for the
pairs “euploidy & T13,” “euploidy & T18,” “euploidy & T21,
T18 & Turner,” “T21 & Triploidy,” and “T21 & Turner,” and
therefore, the results were excluded from Table II.
In Figs. 1 to 5, we use the box plots to present the median,
the standard deviation, the normality of the distribution, and the
outliers of each feature. The total range of each feature is shown
with a vertical dashed line, while the lowest and the highest
values are shown with small horizontal lines at its ends. The
box in the middle represents the distribution of the feature in
the range between the points of the first quartile (Q1) and the
third quartile (Q3), where Q1 is defined as the middle number
between the smallest number and the median of the dataset.
Similarly, Q3 is defined as the middle value between the median
and the highest value of the dataset. The median of each feature
is shown with a small horizontal line within the box. In each
figure, a box plot of a feature is plotted against all the 6 classes.
A dashed and a solid horizontal lines show the median of the
euploidy and the median of the T21, respectively. These two
lines were placed manually for visualization purposes.
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Fig. 1. Visualization of statistical properties of the CRL feature.
Fig. 2. Visualization of statistical properties of the β-hCG MoM feature.
Fig. 3. Visualization of statistical properties of the Delta NT feature.
The purpose of this analysis is to gain additional knowl-
edge about the statistical properties and the significance of the
separability of every feature. For instance, the medians of the
populations of each class can be roughly compared by simply
observing the distance between them. Also, it is interesting to
Fig. 4. Visualization of statistical properties of the Mother’s age feature.
Fig. 5. Visualization of statistical properties of the PAPP-A MoM feature.
visualize how the distribution around the median is spread. This
can be done by observing the area enclosed in the box around
the median. The normality of the distribution can also be ob-
served if the median lies in the middle of the box. The outliers
are also marked by a cross allowing a rapid way to estimate their
population and their statistical significance with respect to the
distance from the median.
Fig. 1 shows statistical information of the fetal CRL param-
eter. The value of the CRL is extracted during the ultrasound
screening. The doctor is manually annotating the preferred po-
sitions of the crown ramp by looking at the fetus on the screen.
The manual annotation of the CRL creates a possibility for hu-
man errors in the measurement. Indeed, it may be that the high
variance of the data for all the classes can be explained due
to this observer error. It is worth mentioning that the median
of the T21 is significantly higher from the euploidy, while the
median of the O.C.A. is lower. This fact also explains that a
system which in the training procedure takes all the trisomies as
a single class may not achieve a robust generalization.
In Fig. 2, it is shown that the variance of the data for the serum
free β-hCG feature is narrow with an exception on the data of
the triploidy. As can be seen, there is one extreme outlier that
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TABLE III
NUMBER OF CASES THAT WERE USED FOR TRAINING IN THE
CROSS-VALIDATION PROCEDURE
Training Euploidy T21 T18 T13 Triploidy Turner
Fold 1 33,619 279 106 38 22 41
Fold 2 33,840 278 105 39 23 40
Fold 3 33,982 277 104 37 24 39
forces the data to a non-Gaussian distribution. This is reason-
able, taking into account the small population of in this class.
The feature serum-free β-hCG has high separability by means
of their median, for the pair “euploidy & T21” and low separa-
bility for the pairs “euploidy & Turner,” “T13 & Triploidy,” and
“T18 & Triploidy.”
The analysis of the feature Delta NT is shown in Fig. 3.
The variance of the data in the classes T13, T18, and Turner
is relatively higher with respect to the data in the euploidy and
triploidy classes. It is also shown that the separability between
the euploidy and the trisomies T13, T18, T21, and Turner has
statistical significance.
It is well known that the MA plays a significant role for the
classification of the euploidy or T21. This can also be observed
in Fig. 4. The mean MA of the euploidy is 33 years, while
for the T21, it is 38 years. It can also be seen that the means
of euploidy and triploidy do not have significant statistical dif-
ferences. While the mean of the MA of T21, T13, and T18 is
significantly higher, the mean for Turner is significantly lower.
This can be seen in Fig. 4 and, mathematically, by the Wilcoxon
Rank Sum method, shown in Table II.
There is a statistical significance in the difference of the means
between euploidy and the rest of the trisomies for the feature
PAPP-A. In Fig. 5, it is shown that the mean of the euploidy
has a higher value with respect to the means of the O.C.A. The
variance of all the classes for this feature is relatively low. In
addition to the statistical analysis done in these data and the
useful information regarding the nature of the data, an expert
obstetrician can use these graphs while examining a new case. It
can provide to him a tool for visualizing a new case with respect
to thousands of previously confirmed cases.
D. Cross Validation
The systems and approach described in this paper were tested
with a threefold cross validation. This was done by randomly
dividing the data of 51,208 (50,517 euploidy, 408 T21, and
283 O.C.A.) pregnancies into three training and evaluation sets
containing proportionally the same numbers of euploidy and
aneuploidy cases, as shown in Tables III and IV.
E. System 1: Classification Into Two Classes: Euploidy
and T21
The dataset was split into a training and an evaluation set. The
training dataset consisted only of euploidy and T21 pregnancies
(Fig. 6), whereas the evaluation set also contained cases with
O.C.A. Various supervised models with ANN, SVM (kernel 1
TABLE IV
NUMBER OF CASES THAT WERE USED FOR VALIDATION IN THE
CROSS-VALIDATION PROCEDURE
Validation Euploidy T21 T18 T13 Triploidy Turner
Fold 1 16,898 129 39 14 10 13
Fold 2 16,677 130 40 13 9 14
Fold 3 16,535 131 41 15 8 15
Fig. 6. System 1, distinguishing between euploidy and T21 for the 9-input
ANN. In this system, the training set contained only euploidy and T21 cases.
The evaluation set contained euploidy, T21, and O.C.A.
TABLE V
PARAMETERS USED AS INPUT VECTORS FOR THE TRAINING MODELS
Parameter Model of 6 inputs Model of 9 inputs
Maternal age Used Used
History of previous T21 Used Used
Crown ramp length Used Used
Delta nuchal translucency Used Used
Serum PAPP-A Used Used
Serum free β -hCG Used Used
Nasal bone Not Used Used
Ductus venosus flow Not Used Used
Tricuspid flow Not Used Used
and 2), and k-NN were developed and the best results in sepa-
rating euploidy from T21 pregnancies were achieved by using a
standard multilayer feed-forward neural network with one hid-
den layer. There were 9 neurons in the input layer, representing
the 9 markers that were used for training the networks (see Ta-
ble V). The network output target was set to 0 for T21 and 1 for
euploidy.
After completion of the learning process through the use of the
training dataset, the system was tested by the evaluation dataset,
which consisted of euploidy, T21, and O.C.A. It is important
to mention that system 1 can be considered as an autonomous
system where T21 cases are detected with considerably low
FPR. The drawback of this system is that the O.C.A. are mostly
predicted as euploidy. These false negative predictions of the
O.C.A. are important to be identified as abnormalities. While
generally the O.C.A. have an increased possibility of miscar-
riage during pregnancy, and therefore, the early diagnosis of
such abnormalities are not considered to have equal importance
to the T21, in some cases, the embryo survives until the late
stages of pregnancy, or it is born and die few days later. This
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fact may cause health complications to the mother and generate
additional psychological damage to the relatives.
In order to predict correctly the O.C.A., we propose system
2 that minimizes the false negative rate (FNR) with a cost of
increasing the FPR and creating false alarm to some families.
The doctors may use system 1 or system 2, having in mind
the cost and the risk of sending a euploidy for further invasive
examinations or considering an abnormal case as euploidy and
let the pregnancy continue naturally.
F. System 2: Separate Classification of Three Classes:
Euploidies, T21, and All the O.C.A.
The same approach followed in developing system 1 had been
followed for generating suitable classification models that could
separate not only T21 from euploidy cases but also to test for
the capability to separate the O.C.A. from the euploidy cases.
In a first attempt, we tried to build a neural network that
could predict 6 situations. These were set as the outputs of
the ANN. They were the euploidy, T21, trisomy 18, trisomy 13,
Turner syndrome, and triploidy. Although the cases of T21 were
separable from euploidy, when the O.C.A. were involved during
the training phase of the network, this separation deteriorated
and most of the O.C.A. were classified as euploidy. Thus, this
approach was abandoned.
A second approach that we tested was to build neural networks
that were trained to separate euploidy from T21, euploidy from
trisomy 18, euploidy from trisomy 13, euploidy from Turner
syndrome, euploidy from triploidy, and T21 from O.C.A. This
approach was also abandoned since it failed to successfully sep-
arate the groups. It was observed, however, that most of the false
positive cases (i.e., euploidy cases classified as aneuploidy) were
the same for all the models examined. Thus, it was decided to ex-
clude the models “euploidy & T13” and “euploidy & triploidy”
from the overall system due to very low performance and com-
bine the results of the tree systems in a logical way (“euploidy &
T21,” “euploidy & T18,” and “euploidy & Turner syndrome”).
System 2 was, therefore, decided to involve two stages for
distinguishing between euploidy, T21, and aneuploidy pregnan-
cies. In stage 1, each case is assessed independently by the three
models explained above and classified as euploidy or aneuploidy
(T21, trisomy 18, or Turner syndrome). This is done with the
logical statement: “If a case is classified as euploidy by all three
models, then this case is given a final classification as euploidy,
otherwise is send to stage 2 for further examination.” In Stage 2,
any case given an aneuploidy result by any of the three models is
reassessed by a 9-input model of “T21 & O.C.A.” with a binary
output (0 for T21 and 1 for O.C.A.) and reclassified into T21 or
O.C.A. as shown in Fig. 7.
III. RESULTS
We present our results in terms of detection rate, the ac-
curacy, and Matthews correlation coefficient (MCC) [32]. A
correct classification of an abnormal case is called true posi-
tive prediction (TP), while a false classification of an abnormal
case is called false negative prediction (FN). True negative (TN)
and false positive (FP) are the correct and false classification,
Fig. 7. System 2, distinguishing between euploidy, T21, and O.C.A. It is a
combination of four ANN trained with 1) euploidy and T21, 2) euploidy and
T18, 3) euploidy and Turner, and 4) T21 and O.C.A.
TABLE VI
ACCURACY AND THE MATTHEWS CORRELATION COEFFICIENT (MCC) OF THE
ANN, SVM AND K-NN OF SYSTEM 1 FOR THE FIRST VALIDATION DATASET.
SYSTEM 1 WAS TRAINED WITH EUPLOIDY AND T21 CASES. IT WAS VALIDATED
FOR THE ENTIRE DATABASE INCLUDING EUPLOIDY, T21 AND O.C.A.
System 1 Accuracy MCC
ANN 0.96 0.40
SVM 1 0.93 0.31
SVM 2 0.92 0.28
k-NN 0.92 0.28
respectively, for a normal case. The detection rate is defined as
the correctly classified instances divided by the total population
of each class. The accuracy is defined as the sum of true pos-
itives and true negatives divided by the total population. The
MCC is a balanced measure of the quality of binary classifica-
tions in the range−1 and 1, and it is commonly used to describe
the results of highly unbalanced class populations. A value of
−1 represents a complete error of classification, while a value
of 1 represents perfect classification. A value of 0 shows ran-
dom classification. It was introduced by the biochemist Brian




A. System 1: Classification Into Two Classes: Euploidy
and T21
The results of System 1 for fold 1 and for ANN, SVM
(kernel 1 and 2), and k-NN are summarized in Table VI. The
results of the threefold cross validation for ANN are shown in
Table VII. In Table VIII, we present the histogram of the 9-input
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TABLE VII
DETECTION RATES OF ANN OF SYSTEM 1 FOR THE THREE VALIDATION
DATASETS. SYSTEM 1 WAS TRAINED WITH EUPLOIDY AND T21
CASES. IT WAS VALIDATED FOR THE ENTIRE DATABASE INCLUDING
EUPLOIDY, T21, AND O.C.A.
System 1 Euploidy T21 O.C.A.
Fold 1 96.1% 100.0% 27.6%
Fold 2 97.1% 93.9% 57.9%
Fold 3 97.2% 90.1% 65.8%
TABLE VIII
PERFORMANCE OF SYSTEM 1, THE 9-INPUT MODEL “EUPLOIDY &
ANEUPLOIDY,” WHERE EACH CASE WAS QUANTIFIED
TO A CLASS BETWEEN 0 AND 1
Output Euploidy n = 16,898 T21 n = 129 O.C.A. n = 76
0 to 0.1 104 (0.6%) 115 (89.2%) 12 (15.8%)
> 0.1 to 0.2 80 (0.5%) 8 (6.2%) 3 (3.9%)
> 0.2 to 0.3 129 (0.8%) 3 (2.3%) 1 (1.3%)
> 0.3 to 0.4 138 (0.8%) 2 (1.6%) 2 (2.6%)
>0.4 to 0.5 203 (1.2%) 1 (0.8%) 3 (3.9%)
>0.5 to 0.6 192 (1.1%) – 2 (23.6%)
>0.6 to 0.7 217 (1.3%) – 2 (23.6%)
>0.7 to 0.8 231 (1.4%) – 5 (6.6%)
>0.8 to 0.9 123 (0.7%) – 7 (9.2%)
>0.9 to 1.0 15481 (91.6%) – 39 (51.3%)
network output where in the range 0 to 0.5, the system correctly
identified as abnormal all 129 cases of T21 with an FPR of 3.9%
(Fig. 6). In the case of T21 pregnancies, the average output
value was 0.029 (standard deviation 0.074) and in 123 (95.4%)
of cases the output was in the range of 0 to 0.2. In the euploidy
pregnancies, the average output value was 0.95 (standard
deviation 0.15) and in 15,604 (92.3%) of cases the output was
in the range of >0.8 to 1. The overall diagnostic yield of the
system was true negative rate (TNR) of 96.1%, FNR of 0%,
true positive rate of 100%, and FPR of 3.9%. Table VIII has a
particular importance. It is shown that the FPR can be reduced
considerably to 1% by changing the threshold to 0.2, if the
society is ready to support 4.6% of the T21 which will be unde-
tected (FN). This can be interpreted as about 50 births of T21 in
1,000,000 births.
B. System 2: Classification Into Three Classes: Euploidy, T21,
and O.C.A.
System 2 is consisted of two subsystems (Stage 1 and Stage 2).
In Stage 1, the system classifies an unknown case as euploidy
or aneuploidy. In Stage 2, the aneuploidies are being further
classified as T21 or O.C.A. (Fig. 7).
1) Classification Into Euploidy or Aneuploidy by Three Mod-
els.: The network combined the 9-input model “euploidy &
T21” (used in system 1) and the 6-input models “euploidy &
trisomy 18” and “euploidy & Turner” syndrome. This network
correctly classified as euploidy (concordance in all three sys-
tems) 15,820 (93.6%) of the 16,898 euploidy cases and as ane-
uploidy (in any one of the three systems) 196 (95.6%) of the
205 aneuploidy cases, including all 129 cases of T21 (100%),
Fig. 8. TPR (filled line) and TNR (dashed line) for the network “euploidy &
T21.” The three plots show the results for the three validation sets (folds 1, 2,
and 3).
34 (87.2%) of the 39 cases of trisomy 18, 11 (78.6%) of the 14
cases of trisomy 13, eight (80%) of the ten cases of triploidy,
and 11 (84.6%) of the 13 cases of Turner syndrome (see Fig. 7).
Therefore, at the end of Stage 1, 1,274 cases were classified as
aneuploidy, including 1,078 euploidy pregnancies (FPR 6.4%),
and 15,829 cases were classified as euploidy, including 15,820
(99.9%) which were truly euploidy and 9 of the O.C.A. The
detection rate of the euploidy of SVMs with kernel 1 and 2 in
Stage 1 is 93.4% and 92.2% and for the aneuploidies 73.2% and
72.68%, respectively. The k-NN classified correctly 91.7% of
the euploidy and 74.2 of the aneuploidies.
The TPR and TNR for the networks trained with “euploidy
& T21,” “euploidy & T18,” and “euploidy & Turner” are shown
in Figs. 8–10 for the three evaluation datasets, labeled as fold 1,
fold 2, and fold 3. We present the values of the TPR and TNR for
different values of the threshold that were used to quantize the
outputs of the networks and classify instances into the desired
classes.
We tested several values of the threshold in the range between
0 and 1 with a step of 0.1. The first plot in Fig. 8 shows the
results of the network “euploidy & T21.” The TPR for the T21
aneuploidies is plotted with black continuous line and with black
dashed line the TNR for the first evaluation dataset (fold 1). This
network was used individually to construct system 1, while it is
also used as a subpart in system 2.
The TPR reaches maximum rate 100.0% at a 0.48 threshold.
The FPR at the maximum TPR is 3.9%. The results of the second
and the third evaluation datasets are shown in the next two plots,
respectively, in Fig. 8.
The results of the network “eupoid & T18” for the three
validation datasets are shown in Fig. 9. The TPR of the trisomy
18 cases reaches maximum rate 89.8% at an FPR of 2.6% and
threshold 0.98 for the first evaluation dataset. The TPR of the
NEOCLEOUS et al.: FIRST TRIMESTER NONINVASIVE PRENATAL DIAGNOSIS: A COMPUTATIONAL INTELLIGENCE APPROACH 1435
Fig. 9. TPR (filled line) and TNR (dashed line) for the network “euploidy &
T18.” The three plots show the results for the three validation sets (folds 1, 2,
and 3).
Fig. 10. TPR (filled line) and TNR (dashed line) for the network “euploidy &
Turner.” The three plots show the results for the three validation sets (folds 1,
2, and 3).
second and third evaluation dataset at around 3% FPR is 92.5%
and 90.2%, respectively.
The results of the network “euploidy & Turner” for the three
validation datasets are shown in Fig. 10. The TPR for the first
evaluation dataset of the Turner cases reaches maximum rate
76.9% at an FPR of 1.3% and threshold 0.98. The TPR of the
second evaluation dataset reaches maximum rate 100.0% at an
FPR of 1.7%. The TPR of the third evaluation dataset reaches
maximum rate 66.7% at an FPR of 3.0%.
2) Classification Into T21 or O.C.A.: The 1,274 cases clas-
sified as aneuploidy in Stage 1 were examined by the 9-
TABLE IX
ACCURACY AND THE MATTHEWS CORRELATION COEFFICIENT OF THE ANN,
SVM AND K-NN OF SYSTEM 2, STAGE 2 FOR THE FIRST VALIDATION DATASET.
SYSTEM 2 IN STAGE 2 WAS TRAINED WITH T21 AND O.C.A. IT WAS VALIDATED
FOR THE ENTIRE DATABASE INCLUDING EUPLOIDY, T21 AND O.C.A.
System 2 Accuracy MCC
ANN 0.94 0.88
SVM 1 0.64 0.13
SVM 2 0.64 0.11
k-NN 0.51 -0.05
TABLE X
DETECTION RATES OF THE ANN OF THE SYSTEM 2 IN STAGE 2. SYSTEM 2 IS
CONSISTED BY ONE NEURAL NETWORK BUILD WITH T21 AND O.C.A.
System 2 stage 2 Euploidy T21 O.C.A.
Fold 1 93.7% 100.0% 84.2%
Fold 2 96.7% 90.0% 57.9%
Fold 3 96.2 % 87.8% 44.3%
input model “T21 & O.C.A.” in Stage 2 (Fig. 7). The output
values for all cases of T21 were 0 to 0.1, whereas the values
of the O.C.A. were mostly distributed near to 1. In 64 (95.5 %)
of the 67 O.C.A., the output was more than 0.1, and therefore,
three of these cases were wrongly classified as T21. SVMs with
kernel 1 and kernel 2 classified 98.5% and 97.7% of the T21
and 6.6% of the O.C.A. k-NN classified 62.0% of the T21 and
32.9% of the O.C.A.
The accuracy and MCC of the ANN, SVM, and k-NN for the
System 2 in Stage 2 for the first fold validation are summarized
in Table IX. The detection rates of the first, second, and the third
validation sets for the ANN are summarized in Table X. It is
shown from Table IX that only ANNs were able to separate T21
from the O.C.A., while SVM and k-NN failed.
IV. DISCUSSION
The findings of our studies demonstrate the value of
ANN schemes in the prediction of T21 and O.C.A. from
ultrasonographic and biochemical markers at 11–13 weeks of
gestation.
A multitude of ANN structures, training procedures, and eval-
uation strategies have been tried. In this study, we used multi-
layer feedforward neural systems because these are proved to be
the most suitable from the point of view of satisfactory gener-
alization and diagnostic yield for such predictive systems. This
was confirmed empirically by the authors after running several
ANN models with different structures and parameters and ob-
serving their performance. The various multilayer networks of
neurons were build and adjusted according to a set of param-
eters for each case of either euploidy or aneuploidy fetus in
order to maximize the correct identification of each group. We
have carried out a comparative study by using other classifica-
tion techniques such as the SVMs and the k-NNs. The higher
accuracy on the classification of euploidy, T21, and O.C.A. was
achieved with neural networks structures.
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In the traditional approach to first trimester screening for T21,
the a priori risk is multiplied with the LR of each sonographic
and biochemical marker. Algorithms combining 6 parameters,
including MA, previous history of aneuploidy, delta NT, serum-
free β-hCG MoM, and PAPP-A, MoM have been successfully
applied to screening for T21 achieving a detection rate of about
90.0%, at an FPR of 5.0% [4]. In specialist fetal medicine cen-
ters, the performance of screening can be improved further, with
an increase in detection rate to about 95.0% and a decrease in
FPR to less than 3.0%, by the inclusion the additional sono-
graphic markers of presence or absence of the fetal nasal bone
and normal or abnormal blood flow across the tricuspid valve
and in the ductus venosus [4].
In this study, we initially attempted to develop a supervised
ANN systems with 6 outputs: one each for the euploidy pregnan-
cies and the five chromosomal abnormalities. However, this was
unsuccessful because the cases of T21 were separable, but when
the O.C.A. were in the system, this separation was destructed,
and most of the aneuploidies were classified as euploidy.
Subsequently, we concentrated our efforts at developing neu-
ral network models with the intention of separating euploidy
from T21 pregnancies. One model utilized 6 neurons repre-
senting the basic parameters of MA, previous history, and the
other 9 neurons representing the parameters shown in Table V
columns 1 and 2 respectively. A large database consisting of
33,619 euploidy and 279 T21 pregnancies was used to train
the systems, which were then used for testing the totally un-
known database which included 16,898 euploidy and 129 T21
and 76 OCA pregnancies. The 6-input network correctly iden-
tified 92.3% of the cases of T21 at an FPR of 3.9%, and the
9-input network detected all cases of T21 at an FPR of 3.9%.
The 6-input and 9-input “euploidy & T21” models recog-
nized that 63.2% and 27.6%, respectively, of the aneuploidies
other than T21 were different from euploidy pregnancies. Sub-
sequently, various attempts were made to improve the detection
rate of the O.C.A. by building neural networks that were trained
to separate euploidy from each type of aneuploidy. The per-
formance of neural networks attempting to separate trisomy 13
and triploid from euploidy pregnancies was low, and these mod-
els were abandoned. A two-stage approach involving four neural
networks was then used to achieve the best overall performance.
In Stage 1, each case was assessed independently by three mod-
els (“euploidy & T21,” “euploidy & trisomy 18,” and “euploidy
& Turner syndrome”). This two-stage approach correctly iden-
tified all cases of T21 and 84.2% of the O.C.A. but at an overall
FPR of 6.4%.
Like every methodology, ANN and the computational intel-
ligence approach have relative advantages and disadvantages.
Some of the significant advantages, when compared to the above
methodologies, the proposed approach are as follows.
1) Every case is seen by the system as a string of parameter
values and are thus processed and assessed simultane-
ously. At the same time, data related to the fetus are seen
and assessed together with data that are collected from the
mother.
2) Each new case that has been observed during pregnancy
can become a new definite case once the child delivery
takes place. This new case can add to the acumen of the
existing knowledge base by simply running the learning
algorithm once the new case enters the database.
3) In addition to the above, advantages such as fault tol-
erance, generalization handling, missing data handling,
learning, and inference mechanisms, are advantages in-
herited from computational intelligence.
At present, most medical centers providing first trimester
screening for T21 measure fetal NT and CRL and maternal
serum free β-hCG and PAPP-A. In such centers, the use of
the proposed combined 6-input system could correctly iden-
tify as aneuploidy about 93.0% of the cases of T21 and 63.0%
of those with O.C.A., at an FPR of 3.9%. This performance
of screening compares favorably with the 90.0% detection rate
of T21, at an FPR of 5.0%, achieved by the traditional algo-
rithms for screening [4]. Nevertheless, in all cases classified by
the neural network as being suspicious of T21, invasive test-
ing by chorionic villus sampling or amniocentesis would still
be necessary to distinguish between the euploidy and aneu-
ploidy pregnancies and in the diagnosis of the exact type of
aneuploidy.
In fetal medicine centers, with expertise in assessing the fe-
tal nasal bone and Doppler flow across the tricuspid valve and
in the ductus venosus in addition to the measurements of fetal
NT and CRL and maternal serum free β-hCG and PAPP-A,
there are two options on the use of ANNs. The first is to use a
9-input “euploidy & T21” network which could correctly iden-
tify as aneuploidy all cases of T21 and 27.6% of those with
other major aneuploidies, at an FPR of 3.9%. Alternatively, a
two-stage approach involving four neural networks can be used,
which could also correctly identify as aneuploidy all cases of
T21 and 84% of those with O.C.A., but at an increased FPR
of 6.4%. Since in all cases classified by the neural networks as
being suspicious of T21, invasive testing would be necessary
to distinguish between the euploidy and aneuploidy pregnan-
cies, it is likely that the first option, with a substantially lower
FPR, would be preferred by the parents and would also be more
cost effective. Although the second option identifies more of
the O.C.A., unlike T21, these conditions are highly lethal either
in utero or in the neonatal period, and they are associated with
abnormalities that can be easily detected by ultrasonography.
These include holoprosencephaly, exomphalos and megacystis
in trisomies 18 and 13 [33], large cystic hygromas in Turner
syndrome [34], and either an enlarged partially molar placenta
or small placenta but severely growth restricted fetus with pro-
nounced wasting of the body and sparing of the head in triploidy.
Since the prevalence of these defects is less than 0.1%, the effect
on the overall proportion of pregnancies requiring an invasive
test would be minimal.
V. CONCLUSION
We have presented a noninvasive prenatal diagnosis of chro-
mosomal abnormalities in the first trimester of the pregnancy.
The collection of the database took several years, and it covers
a wide area of population such as age range, ethnicity, informa-
tion whether the mother is alcoholic, drug addicted, cases with
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previous history. The population of the cases in our database en-
sures statistical confidence of our results, compared to databases
used in similar work of other groups. We believe that medical
diagnosis systems that classify instances based on statistical
methods should provide representative databases with a con-
vincing number of population. Also, the results should be pre-
sented with cross validation, ensuring their robustness. The most
important, however, is the fact that our system identifies and pre-
dicts O.C.A. than T21, such as trisomy 18, trisomy 13, Turner
syndrome, and Triploidy. The diagnosis is done in the presence
of a pregnant woman with a computer system in the doctor’s
office by basically using routine examination data within a neg-
ligible time and with low financial cost.
We achieved with ANN a 100.0% detection rate of T21 with
FPR of 3.9% and 84.2% of the O.C.A. with an FPR of 6.4%. We
note that these results do not yield perfect classification, neither
accuracy of 1 since there is still an FPR of 6.4%. We have
repeated the same experiments with SVM and k-NN, and it was
experimentally concluded that the best results for this problem
would be achieved with the ANN. More precisely, SVM and k-
NN yield similar results with lower accuracy than the proposed
ANN structure of both systems 1 and 2. It is also prominent that
both SVM and k-NN were not able to distinguish the T21 from
the O.C.A.
For future work, we need to emphasize our investigations on
exploring other neural network schemes such as recurrent net-
works and the possibility of using parameters from the father.
Preliminary results show that it is worth investigating the sub-
stitution of the parameter values in MoMs with the actual raw
values. It is also worth mentioning that the maternal cell-free
DNA screening method does not use any information from the
mother or the father; such as the age. This important informa-
tion should be included in their methodology and the analysis
of their results.
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